Key result
Persistent post-STEMI microvascular obstruction is linked to ~2.4-fold higher MACE versus transient obstruction.
Why the study?
Microvascular obstruction on CMR predicts adverse prognosis after reperfused STEMI, but the incremental risk associated with persistent microvascular obstruction on late or follow-up imaging is less well defined.
Does persistent microvascular obstruction on cardiac magnetic resonance increase the risk of MACE and death compared with transient or no microvascular obstruction in adults with STEMI treated with primary PCI?
Meta-Analysis (n=2,180)
Does persistent microvascular obstruction on cardiac magnetic resonance increase the risk of MACE and death compared with transient or no microvascular obstruction in adults with STEMI treated with primary PCI?
Persistent microvascular obstruction on cardiac magnetic resonance after primary PCI for STEMI identifies a high-risk phenotype associated with significantly higher rates of MACE, mortality, larger infarct size, and lower LVEF compared to transient or absent microvascular obstruction.
Persistent MVO after STEMI identifies higher-risk patients; extends observational evidence but leaves open whether targeted interventions improve outcomes.
Background Microvascular obstruction after reperfused ST-elevated myocardial infarction (STEMI) predicts adverse prognosis on cardiac magnetic resonance (CMR). The incremental risk associated with persistent microvascular obstruction on late or follow up imaging is less well defined. Methods We searched the literature through January 2026 for cohort studies of adults with STEMI treated with primary PCI who underwent CMR and reported outcomes by persistent microvascular obstruction status. Persistent microvascular obstruction (MVO) was defined on late gadolinium enhancement or follow up scans and was compared with transient microvascular obstruction or no microvascular obstruction. Random effects models pooled risk ratios and mean differences, and heterogeneity was assessed using I². Results Seven cohort studies including 2,180 patients with follow up from 1 month to 5 years were included. Compared with transient MVO, persistent MVO was associated with higher MACE (RR 2.40, 95% CI 1.51–3.81, p=0.0002) (Figure A) and higher death (RR 3.51, 95% CI 1.69–7.29, p=0.0008), with lower LVEF (MD −5.81%, 95% CI −9.04 to −2.58, p=0.0004) and larger infarct size (MD 7.26%, 95% CI 2.98–11.53, p=0.0009). Compared with no MVO, persistent MVO was associated with higher MACE (RR 3.72, 95% CI 2.48–5.60, p<0.0001) (Figure B), higher death (RR 5.90, 95% CI 2.65–13.15, p<0.0001), and higher heart failure readmission (RR 4.80, 95% CI 2.66–8.66, p<0.0001), with lower LVEF (MD −11.33%, 95% CI −17.67 to −4.99, p=0.0005) and larger infarct size (MD 12.75%, 95% CI 6.34–19.17, p<0.0001). Recurrent MI was not significantly different in either comparison, and heart failure readmission did not differ versus transient MVO. Conclusion Persistent microvascular obstruction identifies a high-risk STEMI phenotype with worse long-term outcomes and adverse remodeling markers.
No takes yet. Share an insight, caveat, or question.
Gadelmawla et al. (2026) conducted a meta-analysis in ST-elevated myocardial infarction (STEMI) (n=2,180). Persistent microvascular obstruction (MVO) vs. Transient microvascular obstruction or no microvascular obstruction was evaluated on Major adverse cardiovascular events (MACE) (persistent vs transient MVO) (RR 2.40, 95% CI 1.51-3.81, p=0.0002). Persistent microvascular obstruction after STEMI was associated with higher MACE compared with transient MVO (RR 2.40, 95% CI 1.51–3.81) and no MVO (RR 3.72, 95% CI 2.48–5.60).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: